Hydralazine 25Mg and 50Mg Tablets

Total Page:16

File Type:pdf, Size:1020Kb

Hydralazine 25Mg and 50Mg Tablets Package leaflet: Information for the patient Hydralazine 25mg and 50mg tablets Read all of this leaflet carefully • have angina pectoris, which causes pain in the chest before you start taking this with exercise medicine because it contains • have cerebrovascular disease (narrowing of the blood vessels in the brain) important information for you. • have been told you are a slow acetylator (this means • Keep this leaflet. You may need to that your body handles some medicines more slowly read it again. than other people) • If you have any further questions, • suffer from any serious liver or kidney problems. ask your doctor or pharmacist. Tests • This medicine has been prescribed If you are taking long-term Hydralazine treatment, for you only. Do not pass it on to your doctor may want to carry out blood and urine others. It may harm them, even if tests every 6 months. their signs of illness are the same as yours. Other medicines and Hydralazine tablets • If you get any side effects, talk to Tell your doctor or pharmacist if you are taking, have your doctor or pharmacist. This recently taken or might take any other medicines. includes any possible side effects It is especially important to tell your doctor if you are not listed in this leaflet. See section taking: 4. • medicines for high blood pressure, such as vasodilators (e.g. minoxidil diazoxide) What is in this leaflet • ACE inhibitors (e.g. enalapril, lisinopril, captopril) • Beta-blockers (e.g. propranolol) 1 What Hydralazine tablets are • calcium antagonists (e.g. nifedipine or diltiazem) and what they are used for • medicines for water retention (e.g. diuretics) 2 What you need to know • medicines for problems such as depression, including monoamine oxidase inhibitors (MAOIs) before you take Hydralazine (e.g. moclobemide, phenelzine, isocarboxazid, tablets tranylcypromine) 3 How to take Hydralazine • tricyclic antidepressants (e.g. amitriptyline, clomipramine) or tranquillisers (e.g. diazepam) tablets • medicines to control pain and inflammation (a 4 Possible side effects group of medicines known as non-steroidal anti- inflammatory drugs (NSAIDs)) 5 How to store Hydralazine • medicines to control psychoses tablets • a specific group of medicines known as nitrates, used 6 Contents of the pack and to control blood pressure • oestrogens (a group of female sex hormones used in other information contraception and in treating the menopause) • muscle relaxants (e.g. baclofen, tizonidine) 1 What Hydralazine tablets are and what • medicines that stimulate the nervous system (e.g. they are used for adrenaline, norepinephrine) Hydralazine belongs to a group of medicines called • steroids. vasodilators. These medicines relax the muscles of artery walls and cause blood vessels to expand. If you are going to have general anaesthetic, you Hydralazine tablets are used to: should tell the doctor or dentist in charge that you • treat moderate to severe high blood pressure (with or are taking Hydralazine tablets. without a beta-blocker or diuretic medicine) Hydralazine tablets with alcohol • manage moderate to severe congestive heart failure It is advisable not to drink alcohol whilst taking (where use of other medicines alone is not enough). Hydralazine tablets as it may affect you more than 2 What you need to know before you usual. take Hydralazine tablets Pregnancy and breast-feeding Do not take Hydralazine tablets if you have: If you are pregnant or breast-feeding, think you may • an allergy to hydralazine, dihydralazine or any of the be pregnant or are planning to have a baby, please tell other ingredients in this medicine (listed in section 6) your doctor before taking Hydralazine Tablets. • a racing heart beat (tachycardia) Driving and using machines • heart failure caused by narrowing of blood vessels You can drive while taking Hydralazine but do not or heart valves (aortic or mitral stenosis), high drive until you know how the tablets affect you. They blood pressure in blood vessels supplying the lungs may make you feel dizzy. If they affect you in this way, (pulmonary hypertension) or inflammation of the do not drive or operate any machinery. heart (constrictive pericarditis) • heart failure with a normal or increased output of Hydralazine tablets and lactose blood from the heart (e.g. in thyrotoxicosis) If you have been told you have an intolerance to • systemic lupus erythematosus (SLE) or any related some sugars, contact your doctor before taking this disease medicine, as the 25mg tablets contain lactose. • swelling in a blood vessel wall (aortic aneurism) • (or a relative has) an inherited disorder of the red Hydralazine tablets and E122 blood pigment haemoglobin (porphyria). The 50mg tablets contain the colour E122 which may cause allergic reactions. Warnings and precautions Talk to your doctor or pharmacist before taking 3 How to take Hydralazine tablets Hydralazine tablets if you: Always take Hydralazine tablets exactly as your doctor • have had a heart attack in the past three months has told you. If you are not sure, check with your • have coronary heart disease doctor or pharmacist. Continued top of next column Continued over page 130x210 Leaflet Reel Fed Profile (BST) Hydralazine, Tablets, 25 & 50mg, Hydralazine 25 & 50 mg Tablets PIL - UK 56s - PL JDE No.: 50990760 approved for print/date Item number: BBBA8132 Colours Non Printing Colours 1. 1. Profile Originator: RH Dimensions: 130x210 Black Dimensions: 130x210 (Reel Fed) Origination Date: 04-05-20 Min Body Text Size: 6.4 pt 2. 2. Revision Date: 11-05-20 Supplier: Accord Barnstaple 3. 3. Component: Leaflet for Bottles Revised By: RH 4. 5. Pharmacode: 2205 Proof Round Technical Date sent: n/a 6. 03 Approval Date received: n/a Date Sent: 28-04-20 [email protected] Technologist: RH FMD info NA (not a carton) No Yes Details Technically Approved * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 2 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 01.11.2017 Speak to your doctor before drinking alcohol with this • Blocked or stuffy nose medicine. • Loss of appetite • Weight loss Swallow these tablets with water. • Dizziness • Generally feeling unwell. The recommended dose is: Adults (including the elderly): Rare (may affect up to 1 in 1,000 people) Hypertension: Initially 25mg twice a day or 50mg once • Kidney failure a day. Your doctor may gradually increase this, up to a • A change in the amount of urine produced maximum of 200mg a day. Your doctor will decide on the • A restriction of movement in part of the intestine best dose for you. • A deficiency of certain white blood cells which can result in Chronic congestive heart failure: Treatment should be fever and ulceration of the mouth and throat started in hospital and dosages can vary. The maintenance • An increased number of white blood cells dose is 50mg - 75mg four times a day. • Enlargement of the spleen • A reduction in the number of red and white blood cells Use in children: Not recommended. and platelets in the blood If you take more Hydralazine tablets than you should • Depression If you (or someone else) swallow a lot of the tablets at the • Seeing or hearing things which are not really there same time, or if you think a child may have swallowed any, (hallucinations) contact your nearest hospital casualty department or tell • Inflammation of the nerves which may cause weakness or your doctor immediately. numbness especially in your fingers and toes Symptoms of an overdose include low blood pressure, • Tingling (pins and needles) in your hands or feet racing heart beat, decreased blood flow to the heart, • Disease of the lymph nodes irregular heart beat, coma. • Enlarged eye balls. If you forget to take Hydralazine tablets If you feel very tired, experience unexpected bruising or Do not take a double dose to make up for a forgotten dose. bleeding, or more infections (e.g. colds and sore throats) If you forget to take a dose, take it as soon as you remember than usual please tell your doctor. Your doctor may decide it and then take the next dose at the right time. to conduct tests on your blood periodically as a result of these symptoms. If you stop taking Hydralazine tablets Do not stop treatment early because an increase in blood Reporting of side effects pressure may occur. Talk to your doctor before you stop If you get any side effects, talk to your doctor, pharmacist taking the tablets and follow their advice. or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the If you have any further questions on the use of this Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or medicine, ask your doctor or pharmacist. search for MHRA Yellow Card in the Google Play or Apple App Store. 4 Possible side effects By reporting side effects you can help provide more Like all medicines, this medicine can cause side effects, information on the safety of this medicine. although not everybody gets them. 5 How to store Hydralazine tablets Stop taking the medicine and seek immediate medical Keep out of the sight and reach of children. advice if you notice the following: Do not store above 25°C. Store in the original container. • SLE-type syndrome, which can cause symptoms such as Do not use Hydralazine tablets after the expiry date stated joint pain, fever, change in blood count and skin rash. on the label/carton. The expiry date refers to the last day of • Allergic reactions including itching, skin rash, inflammation that month. of the walls of small blood vessels and difficulty in Do not throw away any medicines via wastewater or breathing.
Recommended publications
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Hypertensive Crises 8.25
    Hypertensive Crises 8.25 Hypertension crises secondary to monoamine oxidase inhibitor–tyramine interactions Monoamine oxidase inhibitor therapy Impaired degradation of intracellular amines Ingestion of (epinephrine, norepinephrine, dopamine) tyramine-containing food Accumulation of catecholamines in Hepatic monamine nerve terminal storage granules oxidase inhibition with decreased Increased circulating oxidative metabolism tyramine level of tyramine Massive release of catecholamines Tachyarrhythmias Vasoconstriction (increased systemic vascular resistance) Severe paroxysm of hypertension Hypertensive encephalopathy Acute hypertensive heart failure with pulmonary edema Intracerebral hemorrhage (Fig. 8-21) (Figs. 8-24 and 8-25) FIGURE 8-32 Hypertensive crises secondary to monoamine oxidase inhibitor–tyramine interactions. Severe paroxysmal hypertension complicated by intracerebral or subarachnoid hemorrhage, hypertensive encephalopathy, or acute hypertensive heart failure can occur in patients treated with monoamine oxidase (MOA) inhibitors after ingestion of certain drugs or tyramine- containing foods [48,49]. Because MAO is required for degradation of intracellular amines, including epinephrine, norepinephrine, and dopamine, MAO inhibitors lead to accumulation of catecholamines within storage granules in nerve terminals. The amino acid tyramine is a potent inducer of neurotransmitter release from nerve terminals. As a result of inhibition of hepatic MAO, ingested tyramine escapes oxidative degradation in the liver. In addition, the high circulating levels of tyramine provoke massive catecholamine release from nerve terminals, resulting in vasoconstriction and a paroxysm of severe hypertension. A hyper- adrenergic syndrome resembling pheochromocytoma then ensues. Symptoms include severe pounding headache, flushing or pallor, profuse diaphoresis, nausea, vomiting, and extreme prostration. The mean increase in blood pressure is 55 mm Hg systolic and 30 mm Hg diastolic [49]. The duration of the attacks varies from 10 minutes to 6 hours.
    [Show full text]
  • Acrolein As a Novel Therapeutic Target for Motor and Sensory Deficits in Spinal Cord Injury
    [Downloaded free from http://www.nrronline.org on Wednesday, September 11, 2019, IP: 128.210.106.129] NEURAL REGENERATION RESEARCH April 2014,Volume 9,Issue 7 www.nrronline.org SPECIAL ISSUE Acrolein as a novel therapeutic target for motor and sensory deficits in spinal cord injury Jonghyuck Park1, 2, Breanne Muratori2, Riyi Shi1, 2 1 Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA 2 Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA Abstract Corresponding author: In the hours to weeks following traumatic spinal cord injuries (SCI), biochemical processes are Riyi Shi, M.D., Ph.D., initiated that further damage the tissue within and surrounding the initial injury site: a process Department of Basic Medical Sciences, termed secondary injury. Acrolein, a highly reactive unsaturated aldehyde, has been shown to play College of Veterinary Medicine, Purdue a major role in the secondary injury by contributing significantly to both motor and sensory defi- University, West Lafayette, IN 47907, cits. In particular, efforts have been made to elucidate the mechanisms of acrolein-mediated dam- USA, [email protected]. age at the cellular level and the resulting paralysis and neuropathic pain. In this review, we will highlight the recent developments in the understanding of the mechanisms of acrolein in motor doi:10.4103/1673-5374.131564 and sensory dysfunction in animal models of SCI. We will also discuss the therapeutic benefits of http://www.nrronline.org/ using acrolein scavengers to attenuate acrolein-mediated neuronal damage following SCI. Accepted: 2014-04-08 Key Words: oxidative stress; spinal cord injury; 3-hydrxypropyl mercapturic acid; acrolein-lysine ad- duct; hydralazine Park J, Muratori B, Shi RY.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,784,177 B2 Cohn Et Al
    USOO6784177B2 (12) United States Patent (10) Patent No.: US 6,784,177 B2 Cohn et al. (45) Date of Patent: Aug. 31, 2004 (54) METHODS USING HYDRALAZINE Massie et al., The American Journal of Cardiology, COMPOUNDS AND SOSORBIDE 40:794-801 (1977). DINTRATE OR ISOSORBIDE Kaplan et al., Annals of Internal Medicine, 84:639-645 MONONTRATE (1976). Bauer et al., Circulation, 84(1):35-39 (1991). (75) Inventors: Jay N. Cohn, Minneapolis, MN (US); The SOLVD Investigators, The New England Journal of Medicine, 327(10):685–691 (1992). Peter Carson, Chevy Chase, MD (US) Ziesche et al., Circulation, 87(6):VI56-VI64 (1993). Rector et al., Circulation, 87(6):VI71-VI77 (1993). (73) Assignee: Nitro Med, Inc., Bedford, MA (US) Carson et al., Journal of Cardiac Failure, 5(3):178-187 (Sep. 10, 1999). (*) Notice: Subject to any disclaimer, the term of this Dries et al, The New England Journal of Medicine, patent is extended or adjusted under 35 340(8):609-616 (Feb. 25, 1999). U.S.C. 154(b) by 18 days. Freedman et al, Drugs, 54 (Supplement 3):41-50 (1997). Sherman et al., Cardiologia, 42(2):177-187 (1997). (21) Appl. No.: 10/210,113 Biegelson et al., Coronary Artery Disease, 10:241-256 (1999). (22) Filed: Aug. 2, 2002 Rudd et al, Am. J. Physiol., 277(46):H732–H739 (1999). (65) Prior Publication Data Hammerman et al, Am. J. Physiol., 277(46):H1579–1592 (1999). US 2004/0023967 A1 Feb. 5, 2004 LoScalzo et al., Transactions of the American and Climato logical ASS., 111:158-163 (2000).
    [Show full text]
  • LF-117708-01 Hydralazine 20Mg-Ml Injection V7
    Package leaflet: Information for the patient 28055763 syringe, this is called an intravenous injection or; • A restriction of movement in part of the intestine; LF-117708-01 - it may be diluted further and injected very slowly • A deficiency of certain white blood cells which into your vein through a drip (intravenous infusion). can result in fever and ulceration of the mouth The recommended dose is 5 to 10 mg by and throat; intravenous injection, and will be repeated if • An increased number of white blood cells; necessary after 20 to 30 minutes. • Enlargement of the spleen; Hydralazine 20mg Powder for Concentrate for Solution for Injection/Infusion • A reduction in the number of red and white blood Your blood pressure will be taken whilst you cells and platelets in the blood; Hydralazine hydrochloride are receiving treatment and the dose adjusted • Depression; to make sure that you have gradual fall in your Read all of this leaflet carefully before you start • have been told you are a slow acetylator • Seeing or hearing things which are not really blood pressure to normal levels. taking this medicine because it (this means that your body handles some there (hallucinations); contains important information for you medicines more slowly than other people); If you are given more medicine than you should • Inflammation of the nerves which may cause weakness - Keep this leaflet. You may need to read it again. • suffer from any serious liver or kidney problems; As this medicine is given to you in hospital it is very or numbness especially in your fingers and toes; - If you have any further questions ask your • have blockage of one or more arteries that supply unlikely that an overdose will happen.
    [Show full text]
  • Toxicological Profile for Hydrazines. US Department Of
    TOXICOLOGICAL PROFILE FOR HYDRAZINES U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry September 1997 HYDRAZINES ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. HYDRAZINES iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 HYDRAZINES vii CONTRIBUTORS CHEMICAL MANAGER(S)/AUTHOR(S): Gangadhar Choudhary, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Hugh IIansen, Ph.D. ATSDR, Division of Toxicology, Atlanta, GA Steve Donkin, Ph.D. Sciences International, Inc., Alexandria, VA Mr. Christopher Kirman Life Systems, Inc., Cleveland, OH THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 1 . Green Border Review. Green Border review assures the consistency with ATSDR policy. 2 . Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points. 3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs. HYDRAZINES ix PEER REVIEW A peer review panel was assembled for hydrazines. The panel consisted of the following members: 1. Dr.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Hydralazine Hydrochloride Tablets, USP8073301/1120Rx Only
    HYDRALAZINE HYDROCHLORIDE- hydralazine hydrochloride tablet, film coated American Health Packaging ---------- Hydralazine Hydrochloride Tablets, USP 8073301/1120 Rx only DESCRIPTION HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is: HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular weight of 196.64. Each tablet for oral administration contains 10 mg, 25 mg, 50 mg, or 100 mg hydrALAZINE hydrochloride, USP. Tablets also contain FD&C Red #40/Allura Red AC Aluminum Lake, hypromellose, lactose anhydrous, light mineral oil, microcrystalline cellulose, magnesium stearate, pregelatinized starch, sodium lauryl sulfate, and titanium dioxide. CLINICAL PHARMACOLOGY Although the precise mechanism of action of hydrALAZINE is not fully understood, the major effects are on the cardiovascular system. HydrALAZINE apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. HydrALAZINE, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state. The peripheral vasodilating effect of hydrALAZINE results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume, and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. HydrALAZINE usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]
  • Drugs Associated with an Increased Falls Risk
    DRUGS ASSOCIATED WITH INCREASED FALL RISK Beverly Hospital PSYCHOTROPICS PSYCHOTROPICS ANTIHYPERTENSIVES NARCOTICS Antidepressants Antipsychotics(Atypical) ACE Inhibitors Acetaminophen-Codeine- Citalopram (Celexa) Clozapine (Clozaril) Benazepril (Lotensin) Caffeine (Tylenol # 1/2/3) Fluoxetine (Prozac) Olanzapine (Zyprexa) Captopril (Capoter) Codeine Fluvoxamine (Luvox) Quetiapine (Seroquel) Perindopril (Coversy) Fentanyl (Sublimaze, Duragesi) Paroxetine (Paxit) Antipsychotics(Neuroleptics) Cilazapril (Inhibace) Hydromorphone (Dilaudid, Sentraline (Zoloft) Chiorpromazine (Largactil) Enalapril (Vasotec) Hydromorph Contin) Venlafaxine (Effexor) Haloperidol (Haldol) Ramipril (Altace) Meperidine (Demerol) Amitriptyline (Elavil) Hydroxyzine (Atarax) Lisinopril (Prinivil, Zestril) Morphine (MOS, MS Contin, Bupropion (Wellbutrin) Lithium Quinapril (Accupril) M-Eston) Clomipramine (Anafranit) Loxapine (Loxapac) Fosinopril (Monopril) Oxycodone (Percocel, Desipramine (Norpramin) Methotrimeprazine (Nozinan Beta Blockers Percodan, OxyContin) Doxepin (Sinequan) Perphenazine (Trilafon) Acebutolo (Sectrail) Pentazocine (Talwin) Imipramine (Tofranit) Prochlorperazine (Stemetil) Atenolol (Tenormin) Note: May be administered with Mirtazapine (Remeron) Risperidone (Resperdal) Bisoprolol (Monocor) dimenhydrinate (Gravol) or Moclobemide (Manerix) Thioridazine (Mellaril) Carvedilol (Coreg) prochlorperazine (Stemeo) which may increase side effects of drowsiness and Nortriptyline (Aventy) Trifluoperazine (Stelazine) Labetalol (Trandate) dizziness. Trazodone
    [Show full text]